Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2004;35:2853-2854

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chang, K.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chang, K.-C.
Related Collections
Right arrowRelated Article

(Stroke. 2004;35:2853.)
© 2004 American Heart Association, Inc.


Original Contributions

Editorial Comment—A Mercy to Victims of Cerebrovascular Diseases

Ku-Chou Chang, MD, Guest Editor

Assistant Professor of Neurology, First Department of Neurology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

The year 2004 has been a year of reinforcing the idea of treating ischemic stroke. Measures for recanalization per endovascular approach are again proved to be feasible in the brain vessels. In this issue of Stroke, Gobin et al report an unprecedented, promising phase I feasibility study of removing clots from occluded vessels by corkscrew Mechanical Embolus Removal in Cerebral Ischemia (Merci) Retrieval System.1 Treating ischemic stroke by embolectomy is not a new concept; however, until this year, the efficacy of the treatment is emerging and not too invasive.

Recently, the US Food and Drug Administration cleared the device for clot removing. Clot removing might be a reasonable way to treat the occluded brain vessels in practice, but the efficacy of treating acute ischemic stroke by this device is not yet unyielding; thus, the indication should be taken as pending approval. The requirements for approval of the efficacy might be as comparable to those applied to prourokinase from the Prolyse in Acute Cerebral Thromboembolism Trial (PROACT) II.2

Although IV recombinant tissue plasminogen activator has been available in many European and Asian countries since 2002, the short time window ruthlessly limited the treatment incidence. Prehospital delay has been more than enough.3 As shown in this study, limited to no patients had been treated in participating centers. Patients were additionally excluded if the arterial stenosis was proximal to the thrombus, in the opinion of the investigator. Either the number of patients screened or the number of the angiograms done before the . . . [Full Text of this Article]


Related Article:

MERCI 1: A Phase 1 Study of Mechanical Embolus Removal in Cerebral Ischemia
Y. Pierre Gobin, Sidney Starkman, Gary R. Duckwiler, Thomas Grobelny, Chelsea S. Kidwell, Reza Jahan, John Pile-Spellman, Alan Segal, Fernando Vinuela, and Jeffrey L. Saver
Stroke 2004 35: 2848-2854. [Abstract] [Full Text] [PDF]